| A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (NCT05338346) | Antengene Discovery Limited | 2022-07-08 |
| Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT (NCT04959903) | Smart Immune SAS | 2022-03-31 |
| Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT (NCT05290545) | Nanfang Hospital, Southern Medical University | 2022-02-15 |
| Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies (NCT06550102) | University Children's Hospital, Zurich | 2022-01-04 |
| A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging (NCT06834412) | Xijing Hospital | 2021-11-03 |
| A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) (NCT05005442) | Merck Sharp & Dohme LLC | 2021-09-28 |
| Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects (NCT04283097) | Kangpu Biopharmaceuticals, Ltd. | 2021-09-13 |
| A Study of TQB3820 in Patients With Hematological Malignancies (NCT05020639) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-08-31 |
| National Longitudinal Cohort of Hematological Diseases (NICHE) - CART (NCT06607289) | Institute of Hematology & Blood Diseases Hospital, China | 2021-06-01 |
| Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies (NCT04878822) | Ospedale di Circolo - Fondazione Macchi | 2021-04-13 |
| Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions (NCT04790747) | Zhejiang University | 2021-03-01 |
| A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT04634552) | Janssen Research & Development, LLC | 2021-02-01 |
| LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies (NCT04657965) | Zhejiang University | 2021-01-15 |
| Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System (NCT04743388) | National and Kapodistrian University of Athens | 2021-01-04 |
| Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies (NCT04662788) | Zhejiang University | 2021-01-01 |
| A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT04557098) | Janssen Research & Development, LLC | 2020-09-17 |
| Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies (NCT04260698) | Gamida Cell ltd | 2020-07-08 |
| Tissue Microarray of Hematological Malignancies (NCT04142372) | Tampere University Hospital | 2020-03-10 |
| Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials (NCT04184869) | Acrotech Biopharma Inc. | 2019-08-05 |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. (NCT02849886) | Centre Hospitalier Universitaire de Besancon | 2019-04-10 |
| Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study) (NCT03802773) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2019-03-14 |
| Durvalumab and Tremelimumab for Pediatric Malignancies (NCT03837899) | AstraZeneca | 2019-03-07 |
| Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT (NCT03733340) | Nanfang Hospital, Southern Medical University | 2018-12-01 |
| Compassionate Use Study of Tenalisib (RP6530) (NCT03711604) | Rhizen Pharmaceuticals SA | 2018-11-28 |
| Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells (NCT03236129) | Assistance Publique - Hôpitaux de Paris | 2018-02-22 |
| Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT03399799) | Janssen Research & Development, LLC | 2017-12-16 |
| Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies (NCT03248479) | Gilead Sciences | 2017-09-08 |
| Safety and Efficacy Evaluation of IM19 Cells (NCT03344705) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2017-08-21 |
| Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (NCT03145181) | Janssen Research & Development, LLC | 2017-05-16 |
| Study of IV CBL0137 in Previously Treated Hematological Subjects (NCT02931110) | Incuron | 2017-01-01 |
| Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation (NCT02828878) | Cellect Biotechnology | 2017-01-01 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS (NCT02730299) | Gamida Cell ltd | 2016-12-16 |
| CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. (NCT03067155) | University Hospital, Ghent | 2016-10-01 |
| Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes (NCT02680795) | Acrotech Biopharma Inc. | 2016-04-27 |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies (NCT02576496) | Mundipharma Research Limited | 2016-04-14 |
| Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib (NCT02824159) | University Hospital, Toulouse | 2016-04-01 |
| MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT (NCT02528682) | Radboud University Medical Center | 2016-01-01 |
| Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant (NCT02611063) | Stefanie Sarantopoulos, MD, PhD. | 2016-01-01 |
| Impact of Child Positioning on Pain During a Lumbar Puncture (NCT02834156) | Centre Hospitalier Universitaire de Nice | 2015-06-30 |
| Molecular Disease Profile of Hematological Malignancies (NCT02459743) | University of Pavia | 2015-02-01 |
| Pasireotide in Prevention of GI Toxicity (NCT02215070) | Anthony Sung, MD | 2015-01-21 |
| B-Cell Hematologic Malignancy Vaccination Registry (NCT02298816) | Wake Forest University Health Sciences | 2014-08-01 |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome (NCT02269592) | Dana-Farber Cancer Institute | 2014-08-01 |
| Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen (NCT02199041) | St. Jude Children's Research Hospital | 2014-07-11 |
| The Good Patient Study (NCT02199548) | St. Jude Children's Research Hospital | 2014-07-01 |
| PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) (NCT02074436) | Emory University | 2014-05-23 |
| Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) (NCT02859623) | Centre Hospitalier Universitaire de Besancon | 2014-01-01 |
| Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis (NCT01916057) | Assistance Publique - Hôpitaux de Paris | 2013-11-19 |
| Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant (NCT02300571) | Fondazione del Piemonte per l'Oncologia | 2013-09-01 |
| A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (NCT01830010) | Novartis Pharmaceuticals | 2013-06-28 |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis (NCT02213822) | Rhode Island Hospital | 2013-05-01 |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM (NCT01816230) | Gamida Cell ltd | 2013-04-01 |
| Impact of Donor-recipient ABO Matching on Haploidentical Stem Cell Transplantation (NCT05103995) | First Affiliated Hospital of Zhejiang University | 2013-01-01 |
| A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors (NCT01725555) | Axelar AB | 2012-10-01 |
| Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer (NCT01607892) | Karyopharm Therapeutics Inc | 2012-07-23 |
| Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB) (NCT01235468) | Dr. Avichai Shimoni MD | 2012-06-01 |
| Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant (NCT01627275) | Mitchell Horwitz, MD | 2012-06-01 |
| Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies (NCT01168882) | Agennix | 2011-11-01 |
| Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens (NCT01428973) | University of Liege | 2011-09-01 |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors (NCT01349101) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-02-10 |
| Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT (NCT01246206) | Barbara Ann Karmanos Cancer Institute | 2010-11-01 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3) (NCT01139164) | Medical University of South Carolina | 2010-06-01 |
| The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH" (NCT01172132) | Assistance Publique - Hôpitaux de Paris | 2009-11-01 |
| Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers (NCT00788684) | AbbVie | 2009-07-21 |
| Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD (NCT00524784) | Hadassah Medical Organization | 2009-06-01 |
| Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? (NCT00892502) | Copenhagen University Hospital at Herlev | 2009-05-01 |
| Exercise During Chemotherapy for Patients With Hematological Malignancies (NCT00884364) | Charite University, Berlin, Germany | 2009-05-01 |
| Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies (NCT00886522) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2009-04-01 |
| Extracorporal Photopheresis Pilot Study (NCT00930566) | Hospices Civils de Lyon | 2009-04-01 |
| Intrabone Cord Blood Transplantation (NCT00838019) | Hospital Clinic of Barcelona | 2009-02-01 |
| Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies (NCT00841724) | Nantes University Hospital | 2009-01-01 |
| Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients (NCT00824993) | M.D. Anderson Cancer Center | 2008-12-09 |
| Trial Of Double Umbilical Cord Blood Transplantation (NCT00763490) | University of Michigan Rogel Cancer Center | 2008-12-01 |
| Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients (NCT01060462) | Janssen Korea, Ltd., Korea | 2008-08-01 |
| A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies (NCT01315132) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2008-04-10 |
| Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings (NCT00603954) | University of Liege | 2008-01-01 |
| Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies (NCT00580450) | University Of Perugia | 2007-12-01 |
| A Prospective Registry for Febrile Events in Patients With Malignant Hemopathies or Subjected to Haematopoietic Stem Cell Transplant (NCT01069887) | Catholic University of the Sacred Heart | 2007-03-01 |
| Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease (NCT00504803) | University of Liege | 2006-12-01 |
| A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies (NCT00506402) | CASI pharmaceuticals, Inc. | 2006-11-01 |
| Rituximab for Prevention of Chronic GVHD (NCT00379587) | Dana-Farber Cancer Institute | 2006-09-01 |
| Reduced Intensity Haploidentical Transplant for Hematological Malignancies (NCT01162096) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2006-09-01 |
| Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) (NCT00506948) | M.D. Anderson Cancer Center | 2006-09-01 |
| An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation (NCT00348959) | St. James's Hospital, Ireland | 2006-08-01 |
| Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients (NCT01820962) | Maastricht University Medical Center | 2006-07-01 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies (NCT00438178) | Gemin X | 2005-10-01 |
| MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies (NCT00129155) | Hospices Civils de Lyon | 2005-02-01 |
| Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) (NCT00557817) | University of Liege | 2004-03-01 |
| STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors (NCT00088101) | Synta Pharmaceuticals Corp. | 2004-02-01 |
| RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT (NCT00163644) | Bayside Health | 2003-11-01 |
| Intermittent Use of Aerosolized Ribavirin for Treatment of RSV (NCT00500578) | M.D. Anderson Cancer Center | 2003-02-01 |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies (NCT00047489) | M.D. Anderson Cancer Center | 2002-12-01 |
| Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies (NCT00423124) | AGC Biologics S.p.A. | 2002-07-01 |
| Dose-range Finding Treosulfan-based Conditioning (NCT01063647) | medac GmbH | 2001-11-01 |
| Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) (NCT00179764) | Ann & Robert H Lurie Children's Hospital of Chicago | 2000-03-10 |
| Nonmyeloablative Stem Cell Transplant in Elderly (NCT00382759) | Azienda Ospedaliera San Giovanni Battista | 2000-03-01 |
| Cologne Cohort of Neutropenic Patients (CoCoNut) (NCT01821456) | University Hospital of Cologne | 1995-01-01 |
| Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting (NCT00876148) | Azienda Ospedaliera San Giovanni Battista | |